Literature DB >> 19563243

Radiant power determination of low-level laser therapy equipment and characterization of its clinical use procedures.

Rinaldo Roberto de Jesus Guirro1, Luciana Cezimbra Weis.   

Abstract

OBJECTIVE: The main objectives of this study were to characterize low-level laser therapy (LLLT) and the physical therapy clinical procedures for its use. BACKGROUND DATA: There are few scientific studies that characterize the calibration of LLLT equipment.
MATERIALS AND METHODS: Forty lasers at 36 physical therapy clinics were selected. The equipment was characterized through data collected from the owner manuals, direct consultation with the manufacturers, and a questionnaire answered by the users. A digital potency analyzer was used to calibrate released mean potency. Qualitative data were presented throughout the descriptive statistics and quantitative data were analyzed by the Wilcoxon/Kruskal-Wallis and Fisher tests (significance, p < 0.05).
RESULTS: The laser equipment was either AsGa (70.5%) or HeNe (23.5%), and 60% was analog and acquired over 5 years ago. The majority of the equipment was used 10-15 times per week and the most frequent density level used was 2 to 4 J/cm(2). Protective goggles were available in only 19.4% of the clinics evaluated. The association between the analyzed categories demonstrated that a lower mean potency was correlated both with equipment acquired over 5 years ago and analog technology. The determined mean potency was lower than the one claimed by the manufacturer (p < 0.05). In 30 cases, the analyzed equipment presented a potency between 3 microW and 5.6 mW; in three cases, the potency was >25 mW; and in seven cases, potency was nonexistent.
CONCLUSION: The analyzed equipment was out-dated and periodical maintenance was not conducted, which was reflected in the low irradiated potency.

Mesh:

Year:  2009        PMID: 19563243     DOI: 10.1089/pho.2008.2361

Source DB:  PubMed          Journal:  Photomed Laser Surg        ISSN: 1549-5418            Impact factor:   2.796


  6 in total

Review 1.  Is there a measure for low power laser dose?

Authors:  Adenilson de Souza da Fonseca
Journal:  Lasers Med Sci       Date:  2018-11-06       Impact factor: 3.161

Review 2.  Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations.

Authors:  Judith A E M Zecha; Judith E Raber-Durlacher; Raj G Nair; Joel B Epstein; Stephen T Sonis; Sharon Elad; Michael R Hamblin; Andrei Barasch; Cesar A Migliorati; Dan M J Milstein; Marie-Thérèse Genot; Liset Lansaat; Ron van der Brink; Josep Arnabat-Dominguez; Lisette van der Molen; Irene Jacobi; Judi van Diessen; Jan de Lange; Ludi E Smeele; Mark M Schubert; René-Jean Bensadoun
Journal:  Support Care Cancer       Date:  2016-03-16       Impact factor: 3.603

3.  Blue Laser Inhibits Bacterial Growth of Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.

Authors:  Natanael Teixeira Alves de Sousa; Marcos Ferracioli Santos; Rosana Caetano Gomes; Hugo Evangelista Brandino; Roberto Martinez; Rinaldo Roberto de Jesus Guirro
Journal:  Photomed Laser Surg       Date:  2015-05       Impact factor: 2.796

4.  Red and infrared laser therapy inhibits in vitro growth of major bacterial species that commonly colonize skin ulcers.

Authors:  Natanael Teixeira Alves de Sousa; Rosana Caetano Gomes; Marcos Ferracioli Santos; Hugo Evangelista Brandino; Roberto Martinez; Rinaldo Roberto de Jesus Guirro
Journal:  Lasers Med Sci       Date:  2016-02-17       Impact factor: 3.161

5.  Laser light sources for photobiomodulation: The role of power and beam characterization in treatment accuracy and reliability.

Authors:  Carlos Eduardo Girasol; Guilherme de Araújo Braz; Luciano Bachmann; Jonathan Celli; Rinaldo Roberto de Jesus Guirro
Journal:  PLoS One       Date:  2022-03-30       Impact factor: 3.240

6.  Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022.

Authors:  Jolien Robijns; Raj G Nair; Joy Lodewijckx; Praveen Arany; Andrei Barasch; Jan M Bjordal; Paolo Bossi; Anne Chilles; Patricia M Corby; Joel B Epstein; Sharon Elad; Reza Fekrazad; Eduardo Rodrigues Fregnani; Marie-Thérèse Genot; Ana M C Ibarra; Michael R Hamblin; Vladimir Heiskanen; Ken Hu; Jean Klastersky; Rajesh Lalla; Sofia Latifian; Arun Maiya; Jeroen Mebis; Cesar A Migliorati; Dan M J Milstein; Barbara Murphy; Judith E Raber-Durlacher; Hendrik J Roseboom; Stephen Sonis; Nathaniel Treister; Yehuda Zadik; René-Jean Bensadoun
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.